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1. Reinserting membrane proteins into a lipid environment such as bicelles and 
nanodiscs provides a native-like environment with more stability than provided 
by surfactants. 
(This thesis, Chapter 2) 
 
2. The stabilized G-protein coupled receptors (StaRs®) can be produced and 
purified in significant quantities, whilst retaining their expected drug-binding 
characteristics, thus allowing a broad range of structural and biophysical 
studies.  
(This thesis, Chapter 3) 
 
3. Fragment-based screening with different biophysical approaches yields very 
different sets of ligands.  
(This thesis, Chapter 4) 
 
4. Use of an α5 integrin fragment as a fusion partner facilitates the expression 
of many rhodopsin-like GPCRs in inclusion bodies at high levels. 
(This thesis, Chapter 5) 
Banères, J.-L. et al., Trends in Biotechnol, 2011, 29, 314-322. 
5. Target immobilized NMR screening (TINS) can be applied successfully to 
intractable receptors across the GPCR superfamily. 
 
6. A better understanding of the process by which ligands bind and modify 
GPCR structure will ultimately help in the design of more selective drugs with 
the appropriate efficacy for the desired physiologic function. 
Kobilka, B.K., BBA, 2007, 1768, 794-807. 
 
7. It is possible for smaller pharmaceutical organizations to compete effectively 
in the fragment-based drug discovery arena because the costs associated with 
establishing a fragment library and a suitable biophysical technique capable of 
detecting weak ligand-protein interactions are minimal in comparison with a 
standard-sized high-throughput screening. 
 
8. Smaller, more polar ligands have a much higher chance of becoming an 
approved drug. 
Congreve M, et al, Prog in Med Chem, 2014, 53, 1-63. 
 
9. Good experimental designs limit the impact of variability and reduce sample 
size requirements. 
 
10. Before you quit, try. 
